Current
3.5×
5-Year Average
4.7×
All-Time High
6.0×
All-Time Low
1.0×
P/S Ratio daily chart for Abbott Laboratories (ABT)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/S Ratio for Abbott Laboratories (ABT) from 2001 to 2025
| 2025 | $218.88B | $44.33B | 4.9× | +0.3× | |
| 2024 | $195.87B | $41.95B | 4.7× | -0.1× | |
| 2023 | $190.87B | $40.11B | 4.8× | +0.4× | |
| 2022 | $190.79B | $43.65B | 4.4× | -1.4× | |
| 2021 | $248.28B | $43.08B | 5.8× | +0.2× | |
| 2020 | $193.93B | $34.61B | 5.6× | +0.8× | |
| 2019 | $153.09B | $31.90B | 4.8× | +0.6× | |
| 2018 | $126.98B | $30.58B | 4.2× | +0.5× | |
| 2017 | $99.51B | $27.39B | 3.6× | +0.9× | |
| 2016 | $56.57B | $20.85B | 2.7× | -0.5× | |
| 2015 | $66.14B | $20.41B | 3.2× | +0.0× | |
| 2014 | $67.89B | $21.25B | 3.2× | +0.5× | |
| 2013 | $59.34B | $21.85B | 2.7× | +1.5× | |
| 2012 | $48.85B | $39.87B | 1.2× | +0.1× | |
| 2011 | $42.32B | $38.85B | 1.1× | +0.1× | |
| 2010 | $35.62B | $35.17B | 1.0× | -0.3× | |
| 2009 | $39.87B | $30.76B | 1.3× | -0.0× | |
| 2008 | $39.46B | $29.53B | 1.3× | -0.3× | |
| 2007 | $41.47B | $25.26B | 1.6× | +0.0× | |
| 2006 | $35.89B | $22.48B | 1.6× | +0.3× | |
| 2005 | $28.85B | $22.34B | 1.3× | -0.4× | |
| 2004 | $34.74B | $20.26B | 1.7× | +0.1× | |
| 2003 | $32.73B | $19.68B | 1.7× | +0.1× | |
| 2002 | $28.09B | $17.68B | 1.6× | -0.8× | |
| 2001 | $39.05B | $16.29B | 2.4× | — |
- 20254.9×
- 20244.7×
- 20234.8×
- 20224.4×
- 20215.8×
- 20205.6×
- 20194.8×
- 20184.2×
- 20173.6×
- 20162.7×
- 20153.2×
- 20143.2×
- 20132.7×
- 20121.2×
- 20111.1×
- 20101.0×
- 20091.3×
- 20081.3×
- 20071.6×
- 20061.6×
- 20051.3×
- 20041.7×
- 20031.7×
- 20021.6×
- 20012.4×
About P/S Ratio at Abbott Laboratories (ABT)
Abbott Laboratories (ABT) P/S ratio is 3.5× as of June 5, 2026. The 5-year average is 4.7×. The sector median currently stands at 3.5×. The current ratio is at the 2th percentile of its own 10-year history.
Abbott Laboratories (ABT) historical P/S ratio has ranged from a low of 1.0× (2011) to a high of 6.0× (2020) in the available daily series.
The price-to-sales (P/S) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) revenue. It is calculated as market cap ÷ TTM revenue (equivalent to share price ÷ TTM revenue per share). Because the denominator (revenue) cannot be negative, P/S is widely used to value unprofitable or pre-profit companies and to make cross-sector comparisons.
Abbott Laboratories P/S Ratio by Year
Abbott Laboratories P/S Ratio 2025: 4.9×
Abbott Laboratories (ABT) P/S ratio in 2025 was 4.9×, expanded from 4.7× the prior year.
Abbott Laboratories P/S Ratio 2024: 4.7×
Abbott Laboratories (ABT) P/S ratio in 2024 was 4.7×, contracted from 4.8× the prior year.
Abbott Laboratories P/S Ratio 2023: 4.8×
Abbott Laboratories (ABT) P/S ratio in 2023 was 4.8×, expanded from 4.4× the prior year.
Abbott Laboratories P/S Ratio 2022: 4.4×
Abbott Laboratories (ABT) P/S ratio in 2022 was 4.4×, contracted from 5.8× the prior year.
Abbott Laboratories P/S Ratio 2021: 5.8×
Abbott Laboratories (ABT) P/S ratio in 2021 was 5.8×.
Sector peers by P/S Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/S Ratio — table
Healthcare peers of Abbott Laboratories (ABT), ranked by P/S ratio.
| 2.1× | |
| 2.1× | |
| 2.1× | |
| 1.9× | |
| 1.9× | |
| 1.7× | |
| 1.6× | |
| 1.6× | |
| 1.4× | |
| 1.4× | |
| 1.1× | |
| 0.8× | |
| 0.7× | |
| 0.6× | |
| 0.6× | |
| 0.5× | |
| 0.3× | |
| 0.3× | |
| 0.3× | |
| 0.2× | |
| 0.2× | |
| 0.2× | |
| 0.2× | |
| 0.2× | |
| 0.1× |
- 2.1×
- 1.7×
- 1.4×
- 1.1×
- 0.7×
- 0.3×
- 0.3×
- 0.2×
- 0.2×
- 0.2×
- 0.1×
Frequently asked questions
Abbott Laboratories (ABT) Key Financials
Charts, filings, and peer comparison for every metric